Skip to main content
Clinical Trials/NCT04060771
NCT04060771UnknownPhase 3

Prospective, Double-blind Study Comparing Palonosetron and Dexamethasone in the Prophylaxis of Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery

Universidade Federal Fluminense1 site in 1 country80 target enrollmentStarted: August 1, 2018Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Enrollment
80
Locations
1
Primary Endpoint
Vomiting

Study Overview

Brief Summary

Background: Postoperative nausea and vomiting (PONV) is one of the main causes of patient and family dissatisfaction, which may delay the onset of oral intake and postpone discharge. In pediatric patients, the incidence of PONV is high, and in some studies it can reach values of 70%. Strabismus surgery is considered an independent risk factor for PONV. Palonosetron is a second generation antiemetic drug, 5-hydroxytryptamine receptor antagonist, with a long half-life, which allows single dose administration and has been shown to be safe and effective in the treatment of chemotherapy induced nausea and vomiting, and has been used with satisfactory results in the prophylaxis of PONV in adult and pediatric patients. Studies involving palonosetron are still scarce.

Detailed Description

Prospective, double-blind study comparing Palonosetron and Dexamethasone in the prophylaxis of Post-Operative Nausea and Vomiting in children submitted to Strabismus surgery ABSTRACT Background: Postoperative nausea and vomiting (PONV) is one of the main causes of patient and family dissatisfaction, which may delay the onset of oral intake and postpone discharge. In pediatric patients, the incidence of PONV is high, and in some studies it can reach values of 70%. Strabismus surgery is considered an independent risk factor for PONV. Palonosetron is a second generation antiemetic drug, 5-hydroxytryptamine receptor antagonist, with a long half-life, which allows single dose administration and has been shown to be safe and effective in the treatment of chemotherapy induced nausea and vomiting, and has been used with satisfactory results in the prophylaxis of PONV in adult and pediatric patients. Studies involving palonosetron are still scarce.

Objective

The study aims to compare the incidence of PONV after intravenous administration of palonosetron or dexamethasone in pediatric patients undergoing elective strabismus surgery under general anesthesia.

Materials and Methods

This prospective, double-blind study consist of 80 patients of both genders, classified as ASA grade I and II, ranging in age from 2 to 15 years, scheduled for elective strabismus surgery at Hospital Universitário Antonio Pedro(HUAP), after consent by their parents. Patients will be randomized into two groups of 40 patients each. Group P will receive intravenous dose of palonosetron (1 mg.kg-1), and Group D will receive dexamethasone (0.2 mg.kg-1) after induction of anesthesia. Pacients will be observed for 6 hours before discharge and post-discharge symptoms will be assessed through telephone survey after 24 and 48 hours. At the end of the study, results will be compiled and statistical analysis will be done by using Mann-Whitney test, Chi-squared test and Fisher test.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Double (Participant, Investigator)

Masking Description

Double-blinded

Eligibility Criteria

Ages
2 Years to 15 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Children undergoing elective strabismus surgery
  • Physical state according to an American Society of Anesthesiologists (ASA) I and II

Exclusion Criteria

  • Children nor involved in surgery
  • Participation in another study in the last month
  • Previous history of PONV
  • Occurrence of episodes of nausea or vomiting in the last 24 hours before surgery
  • Chronic use of corticosteroids
  • Previous history of motion sickness
  • Use of psychoactive drugs or any other medicine with an antiemetic effect;
  • Known hypersensitivity to any study medication
  • Severe diseases in organs such as kidney, liver, lung, heart, brain and bone marrow

Arms & Interventions

Group P

Experimental

During general anesthesia patients will receive a single intravenous dose of palonosetron 1 mcg.Kg-1.

Intervention: Palonosetron (Drug)

Group D

Active Comparator

During general anesthesia patients will receive a single intravenous dose of dexamethasone 0.2 mg.Kg-1.

Intervention: Dexamethasone (Drug)

Outcomes

Primary Outcomes

Vomiting

Time Frame: 48 hours postoperative

Quantify the frequency of individual episodes of vomiting at the first 48 hours after surgery.

Secondary Outcomes

  • Vomiting(2 hours postoperative)
  • Nausea(2h hours postoperative)
  • Check adverse effects(48 hours postoperative)
  • Treatment cost(48 hours postoperative)
  • Response to medication(48 hours postoperative)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Alexandra Rezende Assad, PhD

Professor

Universidade Federal Fluminense

Study Sites (1)

Loading locations...

Similar Trials